Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person8
PERCEPTIVE ADVISORS LLC
Company
Commerce Advisors, LLC
Company
LIBRA ADVISORS LLC
Company
CITADEL ADVISORS LLC
Company
ORBIMED ADVISORS LLC
Company
HAMILTON LANE ADVISORS LLC
Company
Encompass Capital Advisors LLC
Company
Forvis Mazars Wealth Advisors, LLC
Company
Primary record20
Nautilus Biotechnology, Inc. filed SCHEDULE 13D/A
on October 27, 2026. The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. Neither Perceptive Advisors LLC ("Perceptive Advisors") nor Joseph Edelman ("Mr. E
LeonaBio, Inc. filed SCHEDULE 13D/A
0001193125-26-431897.txt : 20261026 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001193125-21-032496 0001224962 XXXXXXXX LIVE 9 Common Stock, $0.0001 par value 10/26/2026 false 0001620463 04746L203 LeonaBio, In
IRulya Therapeutics Inc. filed SCHEDULE 13G
on Form 8-K filed with the Securities and Exchange Commission on October 9, 2026. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 912,853 shares of Co
Kardigan, Inc. filed SCHEDULE 13D/A
on August 11, 2026, and assume the exercise of vested stock options issued to Mr. Giordano in connection with his former service on the Issuer's board of directors. The information set forth in rows 7 through 10 of the c
MacKenzie Realty Capital, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 30, 2026, we announced financial results for the fiscal year ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8
Nurix Therapeutics, Inc. filed SCHEDULE 13G
on July 9, 2026. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 5,536,629 shares of Common Stock. Perceptive Advisors serves as the investment manage
Immatics N.V. filed SCHEDULE 13D/A
on August 25, 2026, and assumes the exercise of vested stock options issued to Adam Stone in connection with his service on the Issuer's board of directors. The information set forth in rows 7 through 10 of the cover pag
LeonaBio, Inc. filed SCHEDULE 13D/A
0001193125-26-365096.txt : 20260825 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001193125-21-032496 0001224962 XXXXXXXX LIVE 8 Common Stock, $0.0001 par value 08/22/2026 false 0001620463 04746L203 LeonaBio, In
PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G/A
on August 6, 2026. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 6,627,501 shares of Common Stock. Perceptive Advisors serves as the investment mana
Inhibikase Therapeutics, Inc. filed SCHEDULE 13G/A
on August 11, 2026, and assume the exercise of Warrants (as defined below) held by the Reporting Persons for 10,320,875 shares of Common Stock. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Com
Nautilus Biotechnology, Inc. filed SCHEDULE 13D/A
on July 28, 2026. The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. Neither Perceptive Advisors LLC ( "Perceptive Advisors") nor Joseph Edelman ("Mr. Ede
PERCEPTIVE ADVISORS LLC filed SCHEDULE 13D/A
on August 6, 2026, and (ii) 139,933 shares of Common Stock issuable upon exercise of vested stock options held by Adam Stone ("Mr. Stone"), the Chief Investment Officer of Perceptive Advisors LLC ("Perceptive Advisors"),
Alto Neuroscience, Inc. filed SCHEDULE 13G/A
on August 12, 2026, and assume the exercise of pre-funded warrants (the "Pre-Funded Warrants") held by the Reporting Persons for 2,566,818 shares of Common Stock. Neither Perceptive Advisors nor Mr. Edelman directly hold
PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G/A
on August 4, 2026. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 4,319,496 shares of Common Stock. Perceptive Advisors serves as the investment mana
PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G/A
on June 15, 2026, and assume the exercise of pre-funded warrants (the "Pre-Funded Warrants") held by the Reporting Persons for 2,077,634 Common Shares. Neither Perceptive Advisors nor Mr. Edelman directly holds any Commo
BlossomHill Therapeutics, Inc. filed SCHEDULE 13G
on August 7, 2026. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 1,808,533 shares of Common Stock. Perceptive Advisors serves as the investment mana
PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G/A
on July 31, 2026. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 1,700,000 shares of Common Stock. Perceptive Advisors serves as the investment manag
PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G/A
on July 30, 2026, and assume the exercise of warrants (the "Warrants") held by the Reporting Persons for 24,605 shares of Common Stock. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stoc
Invivyd, Inc. filed SCHEDULE 13G/A
on August 13, 2026. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 18,490,636 shares of Common Stock. Perceptive Advisors serves as the investment ma
PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G/A
on August 12, 2026. Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 1,304,846 shares of Common Stock. Perceptive Advisors serves as the investment man